Triamcinolone Acetonide .25 mg/g Cream
Other active recalls for Triamcinolone Acetonide (different manufacturers) — 1 · tap to view
🆔 Identity & classification
Where does this data come from?
🏷️ RxNorm drug class
This medicine belongs to the Corticosteroid class.
Where does this data come from?
🏭 Manufacturer & labeler
Where does this data come from?
🩺 Clinical
Triamcinolone topical is used to treat the itching, redness, dryness, crusting, scaling, inflammation, and discomfort of various skin conditions, including psoriasis (a skin disease in which red, scaly patches form on some areas of the body and eczema (a skin disease that causes the skin to be dry and itchy and to sometimes develop red, scaly rashes). It is also used as a dental paste to relieve the discomfort of mouth sores. Triamcinolone is in a class of medications called corticosteroids. It works by activating natural substances in the skin to reduce swelling, redness, and itching.
Read the full MedlinePlus article ↗- Yes, intra-articular triamcinolone is specifically approved to give short-term relief for knee arthritis, gout flares, bursitis, and similar joint conditions. The extended-release...
- I'm getting a triamcinolone injection in my knee. Will it actually help, and how long does it last?
- That's a really important thing to flag with your doctor before your injection or prescription. Triamcinolone can raise blood sugar — even in people whose diabetes is well-controll...
- I have diabetes. Should I be worried about using triamcinolone?
Patient education
Supplement & herbal interactions
Some supplements/herbs that may interact with Triamcinolone Acetonide — tap one for details:
Triamcinolone Acetonide may be associated with lower levels of 8 nutrients — worth a chat with your pharmacist, not a cause for alarm.
Where does this data come from?
Ask a licensed pharmacist directly — free, answered by our team.
💊 What it looks like
Where does this data come from?
🧪 Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
UNII LKG8494WBH
Benzyl alcohol is a clear liquid used as a preservative and solvent in medicines. It helps prevent bacterial and fungal growth and dissolves other ingredients to create uniform liquid formulations.
-
UNII 936JST6JCN
Cetyl alcohol is a waxy, fatty substance derived from plant or animal sources. It acts as an emulsifier and thickener in medicines, helping blend oil and water components and giving products a smooth, creamy texture.
-
UNII PDC6A3C0OX
Glycerin is a clear, thick liquid derived from plant oils or fats. It acts as a humectant to retain moisture, a sweetener, and a solvent in medications.
-
UNII 8CRQ2TH63M
Isopropyl palmitate is an oily liquid derived from palm oil. It acts as an emollient and lubricant in medicines, helping soften the skin or improve how the product spreads and flows.
-
UNII 33X04XA5AT
Lactic acid is a naturally occurring organic acid derived from milk or plant sources. It lowers and maintains pH in formulations, helps preserve the product, and can enhance ingredient stability and absorption.
-
UNII 506T60A25R
Sorbitol is a natural sugar alcohol derived from glucose. It serves as a sweetener, humectant, and bulking agent in medications to improve taste and help maintain moisture in the product.
-
UNII 059QF0KO0R
Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.
7 inactive ingredients listed in the exact product block matched to this NDC.
Where does this data come from?
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
💲 Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per g | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | $0.116 | $1.74 / 15 g |
| Medicaid paysCMS SDUD · 12 mo | $0.3593 | $5.39 / 15 g |
| Medicare drug plans payPart D · Q2 2026 | $0.1230 | $1.85 / 15 g |
Where does this data come from?
🔁 Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Triamcinolone Acetonide .25 mg/g 45802-0063-05 | Padagis | 454 g | $0.036 | AT | Availability likely | save 69% |
| Triamcinolone Acetonide .25 mg/g 45802-0054-05 | Padagis | 454 g | $0.047 | AT | Availability likely | save 59% |
| Triamcinolone Acetonide .25 mg/g 00168-0005-80 | E. | 80 g | $0.076 | AT | Availability likely | save 34% |
| triamcinolone acetonide .25 mg/g 00168-0003-15 | E. | 1 tube | $0.116 | AT | Availability likely | — |
| Triamcinolone Acetonide .25 mg/g 00713-0226-15 | Cosette | 1 tube | $0.116 | AT | Discontinued | — |
| Triamcinolone Acetonide .25 mg/gthis 16714-0985-01 | NorthStar | 1 tube | $0.116 | AT | Availability likely | — |
| Triamcinolone Acetonide .25 mg/g 33342-0327-15 | Macleods | 1 tube | $0.116 | AT | Availability likely | — |
| Triamcinolone Acetonide .25 mg/g 67877-0317-15 | Ascend | 15 g | $0.116 | AT | Availability likely | — |
| Triamcinolone acetonide .25 mg/g 33342-0331-15 | Macleods | 1 tube | $0.244 | AT | Availability likely | +110% |
| Triamcinolone Acetonide .25 mg/g 00713-0229-15 | Cosette | 1 tube | $0.244 | AT | Availability likely | +110% |
| Triamcinolone acetonide .25 mg/g 16714-0267-01 | NorthStar | 1 tube | $0.244 | AT | Availability likely | +110% |
| Triderm .25 mg/g 00316-0165-15 | Crown | 1 tube | — | AT | FDA listed | — |
| triamcinolone acetonide .25 mg/g 50090-0293-01 | A-S | 1 tube | — | AT | FDA listed | — |
| Triamcinolone Acetonide .25 mg/g 50090-2658-00 | A-S | 15 g | — | AT | FDA listed | — |
| Triamcinolone Acetonide .25 mg/g 50090-3704-00 | A-S | 1 tube | — | AT | FDA listed | — |
| Triamcinolone Acetonide .25 mg/g 63187-0214-80 | Proficient | 80 g | — | AT | FDA listed | — |
| Triamcinolone Acetonide .25 mg/g 63629-8782-01 | Bryant | 15 g | — | AT | FDA listed | — |
| Triamcinolone Acetonide .25 mg/g 63629-8784-01 | Bryant | 454 g | — | AT | FDA listed | — |
| Triamcinolone acetonide .25 mg/g 68071-2361-01 | NuCare | 15 g | — | AT | FDA listed | — |
| triamcinolone acetonide .25 mg/g 68788-8515-08 | Preferred | 1 tube | — | AT | FDA listed | — |
| Triamcinolone Acetonide .25 mg/g 68788-8899-01 | Preferred | 15 g | — | AT | FDA listed | — |
| Triamcinolone Acetonide .25 mg/g 71335-2870-01 | Bryant | 454 g | — | AT | FDA listed | — |
| Triamcinolone Acetonide .25 mg/g 72162-1835-02 | Bryant | 454 g | — | AT | FDA listed | — |
| Triamcinolone Acetonide .25 mg/g 72162-2334-02 | Bryant | 1 tube | — | AT | FDA listed | — |
| Triamcinolone Acetonide .25 mg/g 76420-0347-15 | Asclemed | 1 tube | — | AT | FDA listed | — |
| Triamcinolone Acetonide .25 mg/g 76420-0360-80 | Asclemed | 80 g | — | AT | FDA listed | — |
| Triamcinolone Acetonide .25 mg/g 63629-8841-01 | Bryant | 80 g | — | AT | FDA listed | — |
| Triamcinolone Acetonide .25 mg/g 72162-2335-02 | Bryant | 1 tube | — | AT | FDA listed | — |
| Triamcinolone Acetonide .25 mg/g 50090-3802-00 | A-S | 1 tube | — | AT | FDA listed | — |
| Triamcinolone Acetonide .25 mg/g 68788-4148-01 | Preferred | 1 tube | — | AT | FDA listed | — |
Where does this data come from?
⏳ Availability & generic status
This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.
Where does this data come from?
🗺️ Medicaid utilization & spend
💊 Medicaid utilization by pack size
📊 Medicare Part D spend CMS · PART D · 2026 (Q1)
🔬 Reported adverse events (FAERS)
Top reported reactions
Reporter sex
Serious outcomes
Where does this data come from?
📦 Packaging — all sizes for this product
| Package NDC | Description | Per unit | Per pack | Marketing start | Status |
|---|---|---|---|---|---|
| 16714-0985-01 You're viewing this | 1 TUBE in 1 CARTON (16714-985-01) / 15 g in 1 TUBE | $0.1159 / g | $1.74 | 2022-04-21 | Active |
| 16714-0985-02 | 1 TUBE in 1 CARTON (16714-985-02) / 80 g in 1 TUBE | $0.0528 / g | $4.23 | 2022-04-21 | Active |
Per g, this pack runs about 120% above the cheapest pack (NDC 16714-0985-02, $0.0528 vs $0.1159 NADAC).
This pack accounts for about 49% of this product's recent Medicaid fills; most go to a different pack size. See all packs ↓
Pack size FAQ
What quantity is in NDC 16714-0985-01?
What NDC number is used to bill for this package of Triamcinolone Acetonide .25 mg/g Cream?
Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.
📄 Full prescribing information FDA SPL
🎯 Indications and Usage ▾
INDICATIONS & USAGE: Triamcinolone Acetonide Cream is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
⏱️ Dosage and Administration ▾
DOSAGE & ADMINISTRATION: Apply Triamcinolone Acetonide Cream 0.025% to the affected area two to four times daily. Rub in gently. Apply the 0.1% or the 0.5% Triamcinolone Acetonide Cream, as appropriate, to the affected area two to three times daily.
Rub in gently. Occlusive Dressing Technique Occlusive dressings may be used for the management of psoriasis or other recalcitrant conditions. Gently rub a small amount of cream into the lesion until it disappears.
Reapply the preparation leaving a thin coating on the lesion, cover with pliable nonporous film, and seal the edges. If needed, additional moisture may be provided by covering the lesion with a dampened clean cotton cloth before the nonporous film is applied or by briefly wetting the affected area with water immediately prior to applying the medication. The frequency of changing dressings is best determined on an individual basis.
It may be convenient to apply triamcinolone acetonide cream under an occlusive dressing in the evening and to remove the dressing in the morning (i.e., 12-hour occlusion). When utilizing the 12-hour occlusion regimen, additional cream should be applied, without occlusion, during the day. Reapplication is essential at each dressing change.
If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.
⛔ Contraindications ▾
CONTRAINDICATIONS: Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.
🤒 Adverse Reactions ▾
ADVERSE REACTIONS: The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae and miliaria.
🤰 Pregnancy ▾
Pregnancy: Teratogenic Effects Category C. Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals.
There are no adequate and well controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.
🧒 Pediatric Use ▾
Pediatric Use: Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced HPA axis suppression and Cushing's syndrome than mature patients because of a larger skin surface area to body weight ratio. Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation.
Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema. Administration of topical corticosteroids to children should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with the growth and development of children.
🆘 Overdosage ▾
OVERDOSAGE: Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (See PRECAUTIONS ).
🧬 Clinical Pharmacology ▾
CLINICAL PHARMACOLOGY: Topical corticosteroids share anti-inflammatory, anti-pruritic and vasoconstrictive actions. The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids.
There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man. Pharmacokinetics: The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings. Topical corticosteroids can be absorbed from normal intact skin.
Inflammation and/or other disease processes in the skin increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids. Thus, occlusive dressings may be a valuable therapeutic adjunct for treatment of resistant dermatoses (See DOSAGE AND ADMINISTRATION ).
Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys.
Some of the topical corticosteroids and their metabolites are also excreted into the bile.
📦 How Supplied / Storage and Handling ▾
HOW SUPPLIED: Triamcinolone Acetonide Cream USP, 0.025% 15 gram tubes NDC 16714-985-01 80 gram tubes NDC 16714-985-02 Triamcinolone Acetonide Cream USP, 0.1% 15 gram tubes NDC 16714-986-01 30 gram tubes NDC 16714-986-02 80 gram tubes NDC 16714-986-03 1 Lb jars NDC 16714-986-04 Triamcinolone Acetonide Cream USP, 0.5% 15 gram tubes NDC 16714-987-01 Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature]. Avoid excessive heat. PROTECT FROM FREEZING.
Manufactured for: Northstar Rx LLC. Memphis, TN 38141. Manufactured by: Macleods Pharmaceuticals Limited At Oxalis Labs Baddi, Himachal Pradesh, INDIA To report SUSPECT ADVERSE REACTIONS, contact NorthStar Rx LLC 1-800-206-7821 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch Revised: December 2023
📋 Description ▾
DESCRIPTION: The topical corticosteroids constitute a class of primarily synthetic steroids used as anti-inflammatory and anti-pruritic agents. The steroids in this class include triamcinolone acetonide. Triamcinolone Acetonide Cream USP contains Triamcinolone Acetonide [Pregna-1,4-diene-3,20-dione,9-fluoro-11,21-dihydroxy-16,17-[(1-methylethylidene) bis- (oxy)]-, (11β,16α)-], with the empirical formula C 24 H 31 FO 6 and molecular weight 434.50.
CAS 76-25-5. The structural formula is: Triamcinolone Acetonide Cream USP, 0.025% contains: 0.25 mg of Triamcinolone Acetonide, USP per gram in a base containing Emulsifying Wax, Cetyl Alcohol, Isopropyl Palmitate, Sorbitol Solution, Glycerin, Lactic Acid, Benzyl Alcohol and Purified Water. Triamcinolone Acetonide Cream USP, 0.1% contains: 1 mg of Triamcinolone Acetonide, USP per gram in a base containing Emulsifying Wax, Cetyl Alcohol, Isopropyl Palmitate, Sorbitol Solution, Glycerin, Lactic Acid, Benzyl Alcohol and Purified Water.
Triamcinolone Acetonide Cream USP, 0.5% contains: 5 mg of Triamcinolone Acetonide, USP per gram in a base containing Emulsifying Wax, Cetyl Alcohol, Isopropyl Palmitate, Sorbitol Solution, Glycerin, Lactic Acid, Benzyl Alcohol and Purified Water. structure
💬 Information for Patients ▾
Information for the Patient: Patients using topical corticosteroids should receive the following information and instructions. 1. This medication is to be used as directed by the physician.
It is for dermatologic use only. Avoid contact with the eyes. 2.
Patients should be advised not to use this medication for any disorder other than for which it was prescribed. 3. The treated skin area should not be bandaged or otherwise covered or wrapped as to be occlusive unless directed by the physician.
4. Patients should report any signs of local adverse reactions especially under occlusive dressing. 5.
Parents of pediatric patients should be advised not to use tight-fitting diapers or plastic pants on a child being treated in the diaper area, as these garments may constitute occlusive dressings.